Luspatercept Bests Epoetin Alfa in Transfusion-Dependent, Lower-Risk MDS

Back pain (12.1% vs 8.9%); Headache (11.0% vs 8.4%). Rates of progression to acute myeloid leukemia were 2.7% in the luspatercept arm and 3.3% in …
Source: back pain